The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
Identifieur interne : 000375 ( Istex/Corpus ); précédent : 000374; suivant : 000376The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
Auteurs : S. Xie ; M. A. Furjanic ; J. J. Ferrara ; N. R. Mcandrew ; E. L. Ardino ; A. Ngondara ; Y. Bernstein ; K. J. Thomas ; E. Kim ; J. M. Walker ; S. Nagar ; S. J. Ward ; R. B. RaffaSource :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 2007-06.
English descriptors
- KwdEn :
Abstract
There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB1 (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.
Url:
DOI: 10.1111/j.1365-2710.2007.00817.x
Links to Exploration step
ISTEX:2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title><author><name sortKey="Xie, S" sort="Xie, S" uniqKey="Xie S" first="S." last="Xie">S. Xie</name></author><author><name sortKey="Furjanic, M A" sort="Furjanic, M A" uniqKey="Furjanic M" first="M. A." last="Furjanic">M. A. Furjanic</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ferrara, J J" sort="Ferrara, J J" uniqKey="Ferrara J" first="J. J." last="Ferrara">J. J. Ferrara</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Mcandrew, N R" sort="Mcandrew, N R" uniqKey="Mcandrew N" first="N. R." last="Mcandrew">N. R. Mcandrew</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ardino, E L" sort="Ardino, E L" uniqKey="Ardino E" first="E. L." last="Ardino">E. L. Ardino</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ngondara, A" sort="Ngondara, A" uniqKey="Ngondara A" first="A." last="Ngondara">A. Ngondara</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Bernstein, Y" sort="Bernstein, Y" uniqKey="Bernstein Y" first="Y." last="Bernstein">Y. Bernstein</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Thomas, K J" sort="Thomas, K J" uniqKey="Thomas K" first="K. J." last="Thomas">K. J. Thomas</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Kim, E" sort="Kim, E" uniqKey="Kim E" first="E." last="Kim">E. Kim</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Walker, J M" sort="Walker, J M" uniqKey="Walker J" first="J. M." last="Walker">J. M. Walker</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Nagar, S" sort="Nagar, S" uniqKey="Nagar S" first="S." last="Nagar">S. Nagar</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ward, S J" sort="Ward, S J" uniqKey="Ward S" first="S. J." last="Ward">S. J. Ward</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Raffa, R B" sort="Raffa, R B" uniqKey="Raffa R" first="R. B." last="Raffa">R. B. Raffa</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1365-2710.2007.00817.x</idno><idno type="url">https://api.istex.fr/document/2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000375</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000375</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title><author><name sortKey="Xie, S" sort="Xie, S" uniqKey="Xie S" first="S." last="Xie">S. Xie</name></author><author><name sortKey="Furjanic, M A" sort="Furjanic, M A" uniqKey="Furjanic M" first="M. A." last="Furjanic">M. A. Furjanic</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ferrara, J J" sort="Ferrara, J J" uniqKey="Ferrara J" first="J. J." last="Ferrara">J. J. Ferrara</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Mcandrew, N R" sort="Mcandrew, N R" uniqKey="Mcandrew N" first="N. R." last="Mcandrew">N. R. Mcandrew</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ardino, E L" sort="Ardino, E L" uniqKey="Ardino E" first="E. L." last="Ardino">E. L. Ardino</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ngondara, A" sort="Ngondara, A" uniqKey="Ngondara A" first="A." last="Ngondara">A. Ngondara</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Bernstein, Y" sort="Bernstein, Y" uniqKey="Bernstein Y" first="Y." last="Bernstein">Y. Bernstein</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Thomas, K J" sort="Thomas, K J" uniqKey="Thomas K" first="K. J." last="Thomas">K. J. Thomas</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Kim, E" sort="Kim, E" uniqKey="Kim E" first="E." last="Kim">E. Kim</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Walker, J M" sort="Walker, J M" uniqKey="Walker J" first="J. M." last="Walker">J. M. Walker</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Nagar, S" sort="Nagar, S" uniqKey="Nagar S" first="S." last="Nagar">S. Nagar</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Ward, S J" sort="Ward, S J" uniqKey="Ward S" first="S. J." last="Ward">S. J. Ward</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author><author><name sortKey="Raffa, R B" sort="Raffa, R B" uniqKey="Raffa R" first="R. B." last="Raffa">R. B. Raffa</name><affiliation><mods:affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Clinical Pharmacy and Therapeutics</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-06">2007-06</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="209">209</biblScope><biblScope unit="page" to="231">231</biblScope></imprint><idno type="ISSN">0269-4727</idno></series><idno type="istex">2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332</idno><idno type="DOI">10.1111/j.1365-2710.2007.00817.x</idno><idno type="ArticleID">JCPT817</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CB1 receptor</term><term>cannabinoid</term><term>obesity</term><term>rimonabant</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB1 (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>S. Xie Pharm D student</name></json:item><json:item><name>M. A. Furjanic Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>J. J. Ferrara Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>N. R. McAndrew Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>E. L. Ardino Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>A. Ngondara Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>Y. Bernstein Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>K. J. Thomas Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>E. Kim Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>J. M. Walker Pharm D student</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>S. Nagar PhD</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>S. J. Ward PhD</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item><json:item><name>R. B. Raffa PhD</name><affiliations><json:string>Temple University School of Pharmacy, Philadelphia, PA, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>cannabinoid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CB1 receptor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>obesity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rimonabant</value></json:item></subject><articleId><json:string>JCPT817</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB1 (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.</abstract><qualityIndicators><score>7.256</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1331</abstractCharCount><pdfWordCount>12602</pdfWordCount><pdfCharCount>86131</pdfCharCount><pdfPageCount>23</pdfPageCount><abstractWordCount>188</abstractWordCount></qualityIndicators><title>The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title><genre><json:string>review-article</json:string></genre><host><volume>32</volume><publisherId><json:string>JCPT</json:string></publisherId><pages><total>23</total><last>231</last><first>209</first></pages><issn><json:string>0269-4727</json:string></issn><issue>3</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1365-2710</json:string></eissn><title>Journal of Clinical Pharmacy and Therapeutics</title><doi><json:string>10.1111/(ISSN)1365-2710</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>pharmacology & pharmacy</json:string></scienceMetrix></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1111/j.1365-2710.2007.00817.x</json:string></doi><id>2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332</id><score>0.1252308</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title><author xml:id="author-1"><persName><forename type="first">S.</forename><surname>Xie</surname></persName><roleName type="degree">Pharm D student</roleName></author><author xml:id="author-2"><persName><forename type="first">M. A.</forename><surname>Furjanic</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-3"><persName><forename type="first">J. J.</forename><surname>Ferrara</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-4"><persName><forename type="first">N. R.</forename><surname>McAndrew</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-5"><persName><forename type="first">E. L.</forename><surname>Ardino</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-6"><persName><forename type="first">A.</forename><surname>Ngondara</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-7"><persName><forename type="first">Y.</forename><surname>Bernstein</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-8"><persName><forename type="first">K. J.</forename><surname>Thomas</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-9"><persName><forename type="first">E.</forename><surname>Kim</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-10"><persName><forename type="first">J. M.</forename><surname>Walker</surname></persName><roleName type="degree">Pharm D student</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-11"><persName><forename type="first">S.</forename><surname>Nagar</surname></persName><roleName type="degree">PhD</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-12"><persName><forename type="first">S. J.</forename><surname>Ward</surname></persName><roleName type="degree">PhD</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author><author xml:id="author-13"><persName><forename type="first">R. B.</forename><surname>Raffa</surname></persName><roleName type="degree">PhD</roleName><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation></author></analytic><monogr><title level="j">Journal of Clinical Pharmacy and Therapeutics</title><idno type="pISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><idno type="DOI">10.1111/(ISSN)1365-2710</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-06"></date><biblScope unit="volume">32</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="209">209</biblScope><biblScope unit="page" to="231">231</biblScope></imprint></monogr><idno type="istex">2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332</idno><idno type="DOI">10.1111/j.1365-2710.2007.00817.x</idno><idno type="ArticleID">JCPT817</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB1 (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>cannabinoid</term></item><item><term>CB1 receptor</term></item><item><term>obesity</term></item><item><term>rimonabant</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2710</doi><issn type="print">0269-4727</issn><issn type="electronic">1365-2710</issn><idGroup><id type="product" value="JCPT"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="JOURNAL OF CLINICAL PHARMACY THERAPEUTICS">Journal of Clinical Pharmacy and Therapeutics</title></titleGroup></publicationMeta><publicationMeta level="part" position="06003"><doi origin="wiley">10.1111/jcp.2007.32.issue-3</doi><numberingGroup><numbering type="journalVolume" number="32">32</numbering><numbering type="journalIssue" number="3">3</numbering></numberingGroup><coverDate startDate="2007-06">June 2007</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="2" status="forIssue"><doi origin="wiley">10.1111/j.1365-2710.2007.00817.x</doi><idGroup><id type="unit" value="JCPT817"></id></idGroup><countGroup><count type="pageTotal" number="23"></count></countGroup><titleGroup><title type="tocHeading1">Review Article</title></titleGroup><eventGroup><event type="firstOnline" date="2007-05-02"></event><event type="publishedOnlineFinalForm" date="2007-05-02"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-30"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="209">209</numbering><numbering type="pageLast" number="231">231</numbering></numberingGroup><correspondenceTo>Robert B. Raffa, Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19104, USA. Tel.: +1 215 707 4976; fax: +1 215 707 5228; e‐mail: <email>robert.raffa@temple.edu</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JCPT.JCPT817.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 30 January 2007, Accepted 1 March 2007</unparsedEditorialHistory><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="2"></count></countGroup><titleGroup><title type="main">The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB<sub>1</sub> receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title><title type="shortAuthors"><i>S. Xie</i> et al.</title><title type="short"><i>The endocannabinoid system and rimonabant</i></title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" noteRef="#fn1"><personName><givenNames>S.</givenNames><familyName>Xie</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#aff-1-1"><personName><givenNames>M. A.</givenNames><familyName>Furjanic</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#aff-1-1"><personName><givenNames>J. J.</givenNames><familyName>Ferrara</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#aff-1-1"><personName><givenNames>N. R.</givenNames><familyName>McAndrew</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#aff-1-1"><personName><givenNames>E. L.</givenNames><familyName>Ardino</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#aff-1-1"><personName><givenNames>A.</givenNames><familyName>Ngondara</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#aff-1-1"><personName><givenNames>Y.</givenNames><familyName>Bernstein</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#aff-1-1"><personName><givenNames>K. J.</givenNames><familyName>Thomas</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#aff-1-1"><personName><givenNames>E.</givenNames><familyName>Kim</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#aff-1-1"><personName><givenNames>J. M.</givenNames><familyName>Walker</familyName><degrees>Pharm D student</degrees></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#aff-1-1"><personName><givenNames>S.</givenNames><familyName>Nagar</familyName><degrees>PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr12" affiliationRef="#aff-1-1"><personName><givenNames>S. J.</givenNames><familyName>Ward</familyName><degrees>PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr13" affiliationRef="#aff-1-1"><personName><givenNames>R. B.</givenNames><familyName>Raffa</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="US"><unparsedAffiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">cannabinoid</keyword><keyword xml:id="k2">CB<sub>1</sub> receptor</keyword><keyword xml:id="k3">obesity</keyword><keyword xml:id="k4">rimonabant</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Summary</title><p>There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB<sub>1</sub> (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><label>1</label><p> The sequence of the first ten authors was randomly assigned.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>The endocannabinoid system and rimonabant</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Xie</namePart><namePart type="termsOfAddress">Pharm D student</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. A.</namePart><namePart type="family">Furjanic</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. J.</namePart><namePart type="family">Ferrara</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N. R.</namePart><namePart type="family">McAndrew</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E. L.</namePart><namePart type="family">Ardino</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Ngondara</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Bernstein</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K. J.</namePart><namePart type="family">Thomas</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. M.</namePart><namePart type="family">Walker</namePart><namePart type="termsOfAddress">Pharm D student</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Nagar</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. J.</namePart><namePart type="family">Ward</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. B.</namePart><namePart type="family">Raffa</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Temple University School of Pharmacy, Philadelphia, PA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2007-06</dateIssued><edition>Received 30 January 2007, Accepted 1 March 2007</edition><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">2</extent></physicalDescription><abstract lang="en">There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over‐activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Towards this end, antagonists of cannabinoid receptors have been designed through rational drug discovery efforts. Devoid of the abuse concerns that confound and impede the use of cannabinoid receptor agonists for legitimate medical purposes, investigation of the use of cannabinoid receptor antagonists as possible pharmacotherapeutic agents is currently being actively investigated. The compound furthest along this pathway is rimonabant, a selective CB1 (cannabinoid receptor subtype 1) antagonist, or inverse agonist, approved in the European Union and under regulatory review in the United States for the treatment of obesity. This article summarizes the basic science of the endocannabinoid system and the therapeutic potential of cannabinoid receptor antagonists, with emphasis on the treatment of obesity.</abstract><subject lang="en"><genre>keywords</genre><topic>cannabinoid</topic><topic>CB1 receptor</topic><topic>obesity</topic><topic>rimonabant</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Clinical Pharmacy and Therapeutics</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0269-4727</identifier><identifier type="eISSN">1365-2710</identifier><identifier type="DOI">10.1111/(ISSN)1365-2710</identifier><identifier type="PublisherID">JCPT</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>209</start><end>231</end><total>23</total></extent></part></relatedItem><identifier type="istex">2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332</identifier><identifier type="DOI">10.1111/j.1365-2710.2007.00817.x</identifier><identifier type="ArticleID">JCPT817</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000375 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000375 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= DanceTherParkinsonV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2BFD22E21A5419F0BDA91828AEC7DB5F85A4D332
|texte= The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
}}
| This area was generated with Dilib version V0.6.35. |  |